According to the research report, the global biosimilarsmarket size is expected to touch USD 66.2 Billion by 2030, from USD 15.7 Billion in 2022, growing with a significant CAGR of 17.5% from 2022 to 2030.
The biosimilars report offers a
comprehensive study of the current state expected at the major drivers, market
strategies, and key vendors’ growth. The report presents energetic visions to
conclude and study the market size, market hopes, and competitive surroundings.
The research also focuses on the important achievements of the market, research
& development, and regional growth of the leading competitors operating in
the market. The current trends of the global biosimilars in conjunction with
the geographical landscape of this vertical have also been included in this
report.
The report offers intricate dynamics about
different aspects of the global biosimilars market, which aids companies
operating in the market in making strategic development decisions. The study
also elaborates on significant changes that are highly anticipated to configure
growth of the global biosimilars during the forecast period. It also includes a
key indicator assessment that highlights growth prospects of this market and
estimates statistics related to growth of the market in terms of value (US$ Mn)
and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1359
| Report Highlights | Details |
| Market Size | USD 66.2 Billion by 2030 |
| Growth Rate | CAGR 17.5% From 2021 to 2030 |
| Largest Market | Europe |
| Fastest Growing Market | North America |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Application, Region |
This study covers a detailed segmentation
of the global biosimilars market, along with key information and a competition
outlook. The report mentions company profiles of players that are currently
dominating the global biosimilars market, wherein various developments,
expansions, and winning strategies practiced and implemented by leading players
have been presented in detail.
Key Players
- Novartis
- Synthon Pharmaceuticals, Inc.
- TevaPharmaceutical Industries Ltd.
- LG Life Sciences
- Celltrion
- Biocon
- Hospira
- Merck Serono
- Biogen idec, Inc.
- Genentech
Market Segmentation
- Monoclonal Antibodies
- Infliximab
- Retuximab
- Adalimumab
- Trastuzumab
- Glucagon
- Insulin
- Erythropoietin
- Interferon
- Glucagon
- Follitropin
- Alpha
- Beta
- Calcitonin
- Others
By Application
- Oncology
- Lung Cancer
- Brain Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Leukemia or Blood Cancer
- Non-Hodgkin Lymphoma (NHL)
- Chronic Lymphocytic Leukemia (CLL)
- Others
- Others
- Growth Hormonal Deficiency
- Blood Disorders
- Chronic & Autoimmune Disorders
- Infectious Disease
- Others
- Autoimmune disease
- Arthritis
- Rheumatoid arthritis
- Psoriatic arthritis
- Juvenile arthritis
- Ankylosing Spondylitis
- Others
- Inflammatory Bowel Disease (ibd)
- Ulcerative Colitis
- Crohn's Disease
- Others
- Psoriasis
- Others
- Arthritis
- Hematology
- Neutropenia
- Anemia
- Others
- Others
By Manufacturer
- Contract Research and Manufacturing Services
- In-house
By Technology
- Recombinant DNA Technology (rDNA technology)
- Monoclonal Antibodies (MAb) Technology
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Research Methodology
The research methodology adopted by
analysts for compiling the global biosimilars report is based on detailed
primary as well as secondary research. With the help of in-depth insights of
the market-affiliated information that is obtained and legitimated by
market-admissible resources, analysts have offered riveting observations and authentic
forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global biosimilars market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Biosimilars Market
5.1. COVID-19 Landscape: Biosimilars Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Biosimilars Market, By Product
8.1. Biosimilars Market, by Product Type, 2021-2030
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Glucagon
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Insulin
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Erythropoietin
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Interferon
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Calcitonin
8.1.6.1. Market Revenue and Forecast (2019-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Biosimilars Market, By Application
9.1. Biosimilars Market, by Application, 2021-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Growth Hormonal Deficiency
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Blood Disorders
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Chronic & Autoimmune Disorders
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Biosimilars Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
Chapter 11. Company Profiles
11.1. Novartis
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Synthon Pharmaceuticals, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. TevaPharmaceutical Industries Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. LG Life Sciences
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Celltrion
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Biocon
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Hospira
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Merck Serono
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Biogen idec, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Genentech
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments